secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001104659-25-057078
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split
----------------------------------------------------------------------------

- Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.
- Board approved 1-for-100 reverse stock split; outstanding shares reduced from ~64.5M to ~0.6M.
- Post-merger combined company to trade as Crescent Biopharma, Inc. (CBIO) on Nasdaq starting June 16, 2025.
- Combined company expected to have ~14.8M shares outstanding (~25.3M fully diluted) post-merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000110465925057078/0001104659-25-057078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000110465925057078/tm2517051d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-057078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer